First therapeutic application of PAGERs by end of 2025?
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Research publications or clinical trial announcements in relevant therapeutic areas
Stanford Unveils Synthetic GPCRs for Programmable Cell Sensing in Nature Biotechnology
Dec 5, 2024, 12:34 PM
A groundbreaking study from Stanford University introduces synthetic G protein-coupled receptors (GPCRs) designed to sense diverse antigens and trigger a range of intracellular responses. These programmable antigen-gated GPCRs (PAGERs), developed by Alice Y. Ting's lab at Stanford, represent a new frontier in programmable sensing and control of cell behavior, potentially revolutionizing immunotherapy and targeted drug delivery. The technology aims to detect both soluble and cell-attached antigens, converting recognition into intracellular responses like transgene expression and real-time monitoring of cellular processes. This innovation, highlighted in Nature Biotechnology, could lead to the development of programmable expression logic gates, offering new tools for prevention-focused healthcare and enhancing the precision of treatments for various diseases.
View original story
Diagnostics • 25%
Other • 25%
Immunotherapy • 25%
Synthetic Biology • 25%
Yes • 50%
No • 50%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Alzheimer's Disease • 25%
Other • 25%
Schizophrenia • 25%
Parkinson's Disease • 25%
Antimicrobial Resistance Tracking • 25%
Pandemic Monitoring • 25%
Pathogen Detection • 25%
Other • 25%
Autoimmune diseases • 25%
Cancer treatment • 25%
Bacterial infections • 25%
Viral infections • 25%
Education • 25%
Gaming • 25%
Virtual Reality • 25%
Other • 25%
Partnership with NGO • 25%
No further development • 25%
Phase 1 Clinical Trials • 25%
Licensing Agreement • 25%
Other • 25%
Genetic modification • 25%
Cellular reprogramming • 25%
Drug discovery • 25%
Cell • 25%
Science • 25%
Nature • 25%
Other • 25%
China • 25%
United States • 25%
Other • 25%
European Union • 25%